Tolerability/PK study of MAT2203 in patients with a hematologic malignancy
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Amphotericin B (Primary)
- Indications Aspergillosis; Candidiasis; Cryptococcosis; Mycoses; Visceral leishmaniasis; Vulvovaginal candidiasis
- Focus Adverse reactions
- 15 Nov 2017 According to a Matinas BioPharma media release, initial data from the trial is expected in the fourth quarter of 2018.
- 16 May 2017 According to a Matinas BioPharma media release, this trial is expected to initiate in the third quarter of 2017.
- 28 Nov 2016 New trial record